Develop an exemplary anti-thrombotic therapy network data platform and a intelligent terminal application(APP), establish an new pattern used in long-time anti-thrombotic management based on dynamic risk evaluation, and promoted and verified by 10 thousands large sample's cohort study.
1.1.Develop and optimize antithrombotic therapy network data platform and thrombotic risk evaluate the intelligent terminal APP, establish a new pattern based on dynamic risk evaluation and event-triggered response, settle the conundrum in clinical practice about antithrombotic therapy such as poor compliance, lag and unreasonable in drug adjustment. 1.2.Settle the technical problem that intelligent terminal APP code isn't compatible with most tablet PCs and smartphones. 1.3.Impel the data platform to render and integrate with the daily medical system, enhance its accuracy, compatibility, privacy, and quality standard. 1.4.Promote the new pattern of anti-thrombotic management by large sample's cohort study, increase the patients' compliance, reduce the readmission rate and adverse event rate of heart and cerebral vessels.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10,000
Applications(APP) support patients to upload the primary data contain pictures and wearable devices data. When risk-rating changes or serious adverse events(SAE) take place, APP will alert patients to seek medical advice or make a call with the doctor. Beside, terminal of patients furnishes functions like answering frequently asked questions,self-assessment of physical condition,push rehabilitation knowledge etc.
Guangdong General Hospital
Guangzhou, Guangdong, China
RECRUITINGadverse clinical events
net adverse clinical events during 2 years follow-up, including death, myocardial infarction, stroke, ischemia induced target vessel revascularization, BARC type 2-5 bleeding
Time frame: 2 years
BRAC 2-5 type bleeding
defined as bleeding event graded 2 to 5 of Standardized bleeding definitions from the Bleeding Academic Research Consortium（BRAC）
Time frame: 2 years
heart and cerebral vessels ischemia
adeverse events of vascular death, myocardial infarction and stroke
Time frame: 2 years
readmission
incidence of readmission during 2-year follow-up
Time frame: 2 years
angina recurrence
incidence of angina recurrence during 2-year follow-up
Time frame: 2 years
treatment discontinuation
incidence of treatment discontinuation during 2-year follow-up
Time frame: 2 years
drug-related events
incidence of drug-related adverse reaction during 2-year follow-up
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.